First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome.
William MorelloSilvia BudelliDaniel Ari BernsteinTiziana MontemurroElisa MontelaticiCristiana LavazzaLuciana GhioAlberto EdefontiLicia PeruzziDaniela MolinoElisa BenettiBruno GianoglioFlorian MehmetiLaura CatenacciJessica RotellaChiara TamburelloAntonia MorettaLorenza LazzariRosaria GiordanoDaniele PratiGiovanni MontiniPublished in: Stem cell research & therapy (2022)
CB-MSCs are safe and may have a role in the immunosuppressive therapy of pediatric patients with MDR-INS. This preliminary experience paves the way toward further phase II studies addressing MSC efficacy in immune-mediated kidney diseases.